Abstract
This study describes the effect of novel 6-Arylbenzimidazo[1,2-c]quinazoline derivatives as tumor necrosis factor alpha (TNF-alpha) production inhibitors. The newly synthesized compounds were tested for their in vitro ability to inhibit the lipolysaccharide (LPS) induced TNF-alpha secretion in the human promyelocytic cell line HL-60. The compound 6-Phenyl-benzimidazo[1,2-c]quinazoline, coded as Gl, resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-Arylbenzimidazo[1,2-c]quinazoline derivatives may have a potential as anti-inflammatory agents.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents / chemistry
-
Anti-Inflammatory Agents / pharmacology*
-
HL-60 Cells
-
Humans
-
Lipopolysaccharides / pharmacology
-
Quinazolines / chemistry
-
Quinazolines / pharmacology*
-
RNA, Messenger / drug effects
-
RNA, Messenger / metabolism
-
Tetradecanoylphorbol Acetate / analogs & derivatives
-
Tetradecanoylphorbol Acetate / pharmacology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / biosynthesis
Substances
-
Anti-Inflammatory Agents
-
Lipopolysaccharides
-
Quinazolines
-
RNA, Messenger
-
Tumor Necrosis Factor-alpha
-
4-O-methyl-12-O-tetradecanoylphorbol 13-acetate
-
Tetradecanoylphorbol Acetate